



NEWS RELEASE
FOR IMMEDIATE RELEASE

TSX: AMF

AMORFIX ANNOUNCES PRIVATE PLACEMENT

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES
NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, Ontario – April 24, 2009 – Amorfix Life Sciences Ltd., a company focused on treatments and diagnostics for misfolded protein diseases, today announced an offering of up to \$3 million in units (Units) on a non-brokered private placement basis.

Amorfix will use the net proceeds to advance the development and commercialization of its diagnostic and therapeutic programs including its EP-vCJD™ blood screening assay and for general corporate purposes.

The Units are being offered at a price of \$0.65 per Unit and each Unit will consist of one common share and one-half of one common share purchase warrant (Warrant). Each whole Warrant will entitle the holder to purchase one common share of Amorfix at a price of \$1.00 for a period of 24 months following the closing date of the offering. The Warrants are subject to earlier expiry in the event that, following the expiry of the four month hold period, the volume-weighted average price of Amorfix's Common Shares on the TSX over a period of 10 consecutive trading days exceeds \$1.20, in which case Amorfix may give notice to holders to accelerate the expiry to a date which is not less than 30 calendar days after such notice is sent to the holders.

The securities may be issued in one or more closings and will be subject to a four-month hold period from the date of each closing. Closing is subject to Toronto Stock Exchange acceptance.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Amorfix

Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing therapeutic products and diagnostic devices targeting misfolded diseases including neurodegenerative diseases and cancer. It has specific programs in vCJD, ALS and Alzheimer's disease. Amorfix's proprietary Epitope Protection™ (EP) technology enables it to specifically identify very low levels of aggregated misfolded proteins (AMP) in a sample containing normal protein.

Aggregated misfolded proteins are a common element of many brain wasting diseases and cancer. Amorfix has shown antibodies and vaccines to misfolded proteins are therapeutic in preclinical animal models. Amorfix's lead programs are a diagnostic blood screening test for vCJD and a therapy for ALS.

This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

- 30 -

For more information, please contact:

Dr. George Adams
President & Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6959
Fax: (416) 847-6899
george.adams@amorfix.com

James Parsons
Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6929
Fax: (416) 847-6899
james.parsons@amorfix.com